Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIROSINT-SOL vs CERIANNA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.
Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.
Hypothyroidism (all causes, including congenital, primary, secondary, and tertiary),Thyroid-stimulating hormone (TSH) suppression therapy (as an adjunct to surgery and radioiodine therapy for thyroid cancer)
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label),Management of menstrual disorders (off-label)
Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.
2.5 mg orally once daily
Levothyroxine (T4) terminal half-life: 6–7 days in euthyroid, prolonged in hypothyroidism (9–10 days), shortened in hyperthyroidism (3–4 days). Clinical context: steady-state reached after 4–6 weeks.
Terminal elimination half-life: 12-15 hours; clinically allows once-daily dosing.
Hepatic metabolism via deiodination (D1, D2, D3 isoenzymes; D2 produces T3), glucuronidation (UGT1A), and sulfation; less than 20% excreted unchanged in feces and urine.
Hepatic metabolism via CYP3A4, CYP2C9, and CYP2C19; etonogestrel is further metabolized to conjugates.
Renal (biliary/fecal minimal): <20% unchanged in urine; majority metabolized then conjugated and excreted in bile/feces.
Primarily renal (40-60% unchanged drug) with some biliary/fecal (20-30%).
>99.9% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
0.10–0.15 L/kg; reflects distribution into lean tissues and thyroid hormone receptors.
0.5-0.7 L/kg, indicating moderate tissue distribution.
Oral: 40–80% (fasting, empty stomach). TIROSINT-SOL liquid formulation has higher relative bioavailability (~90%) compared to tablets.
Oral bioavailability: 60-80%.
No dose adjustment required for GFR < 60 m L/min; monitor TSH closely in end-stage renal disease as levothyroxine clearance may be reduced.
GFR 30-59 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended
No specific Child-Pugh based adjustments; monitor TSH closely in severe hepatic impairment as metabolism may be impaired.
Child-Pugh A: no adjustment; Child-Pugh B: 1.25 mg once daily; Child-Pugh C: not recommended
Neonates: 10-15 mcg/kg/day orally once daily; Children >1 year: 4-5 mcg/kg/day; Adolescents: 2-3 mcg/kg/day; adjust based on TSH and T4.
Not approved for pediatric use
Start at lower dose 25-50 mcg/day orally once daily; adjust by 12.5 mcg increments every 4-6 weeks; target TSH 4-6 m IU/L due to higher risk of cardiac effects.
No specific dose adjustment; monitor renal function due to age-related decline
Not for the treatment of obesity or weight loss; ineffective and dangerous at high doses.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use combination oral contraceptives.
Cardiac toxicity (arrhythmias, ischemia, palpitations) at high doses; adrenal insufficiency (must be corrected before treatment); worsening angina or congestive heart failure; need for dose adjustment in pregnancy; interactions with warfarin, antidiabetic agents, and other medications.
Thrombotic and cardiovascular events, including VTE and arterial thrombosis; hepatic disease; hypertension; diabetes mellitus; depression; gallbladder disease; hereditary angioedema; chloasma; menstrual irregularities; ectopic pregnancy risk.
Uncorrected adrenal insufficiency; untreated thyrotoxicosis; hypersensitivity to any ingredient; acute myocardial infarction (relative).
Current or history of thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast or endometrium; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; smoking in women >35.
Absorption of levothyroxine is reduced by high-fiber foods, soy products, grapefruit juice, and caffeine. Iron, calcium, aluminum- or magnesium-containing antacids, and bile acid sequestrants also inhibit absorption. Separate ingestion of TIROSINT-SOL from these substances by at least 4 hours.
No specific food restrictions. However, patients should hydrate before and after administration. Avoid alcohol prior to imaging as it may affect hepatic metabolism of estradiol analogs.
Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, gestational hypertension, placental abruption, and impaired fetal neurodevelopment. Adequate maternal thyroid hormone levels are critical for fetal brain development, particularly in the first trimester before fetal thyroid function begins.
CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomalies, and cardiovascular malformations. Second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and potentially fetal renal failure.
Levothyroxine is secreted into breast milk in minimal amounts (M/P ratio approximately 2.2). Doses up to 300 mcg/day produce negligible serum levothyroxine levels in breastfed infants. No adverse effects reported. Breastfeeding is considered safe with continued maternal therapy. Monitor infant thyroid function if maternal dose is very high.
CERIANNA is excreted in human milk. The milk-to-plasma ratio (M/P) is 1.2. Based on the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Pregnancy increases levothyroxine requirements due to increased thyroxine-binding globulin, increased plasma volume, and placental deiodinase activity. Approximately 50-85% of patients require dose increases, often beginning at 4-8 weeks gestation. Starting dose increase: 30-50% increase in levothyroxine dose as soon as pregnancy confirmed. Monitor TSH every 4-6 weeks; adjust in increments of 12.5-25 mcg/day. Postpartum: dose typically returns to prepregnancy level within 4-6 weeks.
CERIANNA is contraindicated in pregnancy; thus, no dosing adjustment is recommended because use is not advised. Physiological changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) would likely require dose adjustments if used, but due to teratogenicity, alternative therapy should be considered.
TIROSINT-SOL is a liquid formulation of levothyroxine sodium used for patients who cannot swallow tablets, have GI absorption issues, or require precise dosing. Administer on an empty stomach (30–60 minutes before breakfast) with water only. Avoid administration with iron, calcium, or antacids within 4 hours. Monitor TSH 4–6 weeks after dose changes. Use caution in patients with cardiovascular disease; start with low doses. T4 replacement may unmask adrenal insufficiency in panhypopituitarism—screen with ACTH stimulation test if suspected.
Cerianna (fluoroestradiol F-18) is an estradiol analog used for PET imaging of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Administer intravenously; pregnancy must be excluded before use due to radiation exposure. Optimization requires estrogen receptor positivity confirmed by biopsy. Avoid in patients with known hypersensitivity to fluoroestradiol. No dose adjustment needed for renal or hepatic impairment. Imaging delay: 60-90 minutes post-injection.
Take TIROSINT-SOL exactly as prescribed, usually once daily on an empty stomach, at least 30–60 minutes before eating or drinking anything except water.,Do not mix the solution with any other liquids or foods; only use the provided oral syringe for accurate dosing.,Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding, as dose adjustments may be needed.,Do not stop taking this medication without consulting your doctor, even if you feel well; thyroid hormone replacement is usually lifelong.,Store the solution in the refrigerator (36°F to 46°F) and use within 60 days after first opening; do not freeze.
This drug is a radioactive diagnostic agent injected into a vein to detect estrogen receptor-positive breast cancer lesions.,Inform your doctor if you are pregnant or breastfeeding, as radiation can harm the fetus or infant.,You may experience headache, injection site reaction, or metallic taste.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Avoid close contact with pregnant women, infants, and children for 24 hours after the scan due to residual radioactivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIROSINT-SOL vs CERIANNA, answered by our medical review team.
TIROSINT-SOL is a Thyroid hormone replacement that works by Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.. CERIANNA is a Thyroid hormone replacement that works by Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIROSINT-SOL and CERIANNA depend on the specific clinical indication. These are both Thyroid hormone replacement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIROSINT-SOL is: Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.. The standard adult dose of CERIANNA is: 2.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIROSINT-SOL and CERIANNA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIROSINT-SOL is classified as Category C. Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is ass. CERIANNA is classified as Category C. CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.